Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2025—Angela Vetch, MPH, DLM(ASCP), is tired of reading about large commercial labs buying hospital laboratories’ outreach business. “There is an alternative to that story,” said Vetch, director of laboratory services at Kootenai Health, a three-hospital system in Coeur d’Alene, Idaho.
September 2025—Enrollment is underway now for a new CAP study that will make it possible for individual and integrated laboratories to compare inpatient analyte volumes and identify ordering practice problems. “This study is the first by the CAP that will allow system laboratories to evaluate a quality metric—inpatient test utilization—across all laboratories within their system and in comparison to like system laboratories across the U.S. and beyond,” says Richard Brown, MD, former chair and now advisor to the CAP Quality Practices Committee, whose members developed the study.
August 2025—There’s the cart before the horse. There are certain equines that should not be flogged; others should not be backed. There’s closing the stable door at an unfortunate time.
August 2025—For routine diagnostic testing, capillary blood is a reliable alternative to venous blood, say the authors of a study published in May. The study was led by Babson Diagnostics, of Austin, Tex., an independent startup spun out of Siemens Healthineers. Babson says it’s the first to validate capillary blood as a viable option for routine testing.
August 2025—The World Health Organization released new guidance this spring to provide aid in implementing patient blood management programs and toolkits to support blood health and patient safety at various resource levels. “It’s the job of the clinician to make the right decisions about blood use at the right time. Patient blood management programs help them do that,” says Sherri Ozawa, MSN, RN, a coauthor of the WHO guidance. “What documents like this and others do is help make the bridge between what laboratory professionals already know and changing clinical practice.” Ozawa is director of patient blood management operations for hc1 of Indianapolis, Ind., a company that optimizes laboratory data to improve clinical practice, enabling better patient care, streamlining operations, and reducing costs.
July 2025—It was one of those infamous winter days in Chicago. The phlebotomy staff were calling off work, and Gregory S. Retzinger, MD, PhD, had reached his breaking point. Phlebotomists tend to be in short supply, and Northwestern Memorial Hospital, where Dr. Retzinger is medical director of pathology clinical services, is no exception.
July 2025—What’s new from Roche, Hologic, and Siemens Healthineers, and how they aim to lighten for labs the burden of the workforce shortage. CAP TODAY publisher Bob McGonnagle spoke about these and other things with three company representatives in an online roundtable, and Stan Schofield, Compass Group managing principal, told them what three questions companies must answer to get a laboratory’s business. Their June 2 conversation follows.
June 2025—The Duffy null phenotype, legal matters, and unmet needs in STI testing are three of the topics on offer at the ADLM meeting next month in Chicago.
May 2025—Fetal RhD prediction by genotyping can prevent unnecessary RhD treatment in some patients and conserve anti-D immunoglobulin. Other countries long ago adopted a targeted antenatal approach to RhD genotyping, and in Canada change is underway.
April 2025—Many look to CAP TODAY to be a central disseminator of news, opinion, and other important information, and it has in the past filled that role in response to others’ requests. One such recent request is that of the Clinical Lab 2.0 movement, established in 2017 by the Project Santa Fe Foundation. We present here, for CAP TODAY readers, the Clinical Lab 2.0 movement’s position paper.
